Shenyang Tonglian Group CO., Ltd   Report issue

For profit Phase 3
Founded: Shenyang China (2003)

Organization Overview

First Clinical Trial
2021
NCT04672564
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Shenyang Tonglian Group Co., Ltd. | Shenyang Tonglian Group CO., Ltd

Active Ingredients

Drugs in Phase 3 Trials (1)

carrimycin (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Coronavirus Infections (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 1
  • # of Trial APIs: 1